-
Innovation Ranking
Innovation Ranking – Orion Corp(G)
Orion Corp (Orion) develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer and respiratory diseases. The company's pipeline encompasses investigational candidates for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Germ Cell Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Germ Cell Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Germ Cell Tumors Drug Details: G-207 is under...
-
Product Insights
NewG Medical Innovations Holdings Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our G Medical Innovations Holdings Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. G Medical Innovations Holdings Ltd (G Medical Innovations ) is a developer of electronic health (eHealth) technologies and mobile health (mHealth) products. It provides continuous, real-time monitoring of vital signs and biometrics of patients. G Medical Innovations is headquartered in Grand Cayman, Cayman Islands, the UK. GlobalData's Medical Devices company profile report, “G Medical Innovations Holdings Ltd...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Primitive Neuroectodermal Tumor (PNET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Primitive Neuroectodermal Tumor (PNET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Primitive Neuroectodermal Tumor (PNET) Drug Details: G-207...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Atypical Teratoid Rhabdoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Atypical Teratoid Rhabdoid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Atypical Teratoid Rhabdoid Tumor Drug Details: G-207...
-
Product Insights
GLP – G-Park Filago Logistics Center – Lombardy
The GLP – G-Park Filago Logistics Center – Lombardy involves the construction of a 25,000m2 logistics center on 5.15ha of land in Filago, Bergamo, Italy. Equip yourself with the essential tools needed to make informed and profitable decisions with our GLP – G-Park Filago Logistics Center – Lombardy report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
GLP – G-Park Landriano Logistics Hub – Lombardy
The GLP – G-Park Landriano Logistics Hub – Lombardy involves the construction of a 17,000m2 logistics hub on 5.5ha of land in Landriano, Milan, Italy. Equip yourself with the essential tools needed to make informed and profitable decisions with our GLP – G-Park Landriano Logistics Hub – Lombardy report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Teserpaturev in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Teserpaturev in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Teserpaturev in Malignant Pleural Mesothelioma Drug Details: Teserpaturev (Delytact) is...
-
Company Insights
NewDecoding Procter & Gamble’s YouTube Advertisement Strategy in Q1 2024
The report on Procter & Gamble's advertising strategies on YouTube during the first quarter of 2024, focus on key products such as Fairy Maxx and Puffs Plus. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Convenience, Efforless Cleaning, Comfort and Relief benefits. Moreover, the report examines the overarching themes of comfort, quality and sustainability infused into these campaigns. By synthesizing these insights, the report aims to provide a nuanced understanding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IVS-3001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IVS-3001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IVS-3001 in Solid Tumor Drug Details: Gene therapy is under development...